ZA956988B - Methods of inhibiting primary endometrial hyperplasia. - Google Patents

Methods of inhibiting primary endometrial hyperplasia.

Info

Publication number
ZA956988B
ZA956988B ZA9506988A ZA956988A ZA956988B ZA 956988 B ZA956988 B ZA 956988B ZA 9506988 A ZA9506988 A ZA 9506988A ZA 956988 A ZA956988 A ZA 956988A ZA 956988 B ZA956988 B ZA 956988B
Authority
ZA
South Africa
Prior art keywords
endometrial hyperplasia
methods
primary endometrial
inhibiting primary
inhibiting
Prior art date
Application number
ZA9506988A
Other languages
English (en)
Inventor
Robin Sharon Lee Fuchs-Young
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA956988B publication Critical patent/ZA956988B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ZA9506988A 1994-08-22 1995-08-21 Methods of inhibiting primary endometrial hyperplasia. ZA956988B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29412194A 1994-08-22 1994-08-22

Publications (1)

Publication Number Publication Date
ZA956988B true ZA956988B (en) 1997-02-21

Family

ID=23131973

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9506988A ZA956988B (en) 1994-08-22 1995-08-21 Methods of inhibiting primary endometrial hyperplasia.

Country Status (20)

Country Link
EP (1) EP0771201B1 (xx)
JP (1) JPH10504579A (xx)
KR (1) KR970705388A (xx)
AT (1) ATE200623T1 (xx)
AU (1) AU706953B2 (xx)
CA (1) CA2198120A1 (xx)
CZ (1) CZ52297A3 (xx)
DE (1) DE69520741T2 (xx)
DK (1) DK0771201T3 (xx)
ES (1) ES2155895T3 (xx)
FI (1) FI970716A0 (xx)
GR (1) GR3036225T3 (xx)
HU (1) HUT76854A (xx)
IL (1) IL115018A0 (xx)
MX (1) MX9701359A (xx)
MY (1) MY131931A (xx)
NO (1) NO970787D0 (xx)
PT (1) PT771201E (xx)
WO (1) WO1996005832A1 (xx)
ZA (1) ZA956988B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2161964C2 (ru) * 1994-08-22 2001-01-20 Эли Лилли Энд Компани Способ ингибирования (угнетения) эндометриального рака
US5843964A (en) * 1994-09-22 1998-12-01 Eli Lilly And Company Methods of inhibiting endometrial mitoses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
JPH07149638A (ja) * 1993-10-15 1995-06-13 Eli Lilly & Co 耐性新生物の治療法

Also Published As

Publication number Publication date
CA2198120A1 (en) 1996-02-29
JPH10504579A (ja) 1998-05-06
AU706953B2 (en) 1999-07-01
HUT76854A (en) 1997-12-29
EP0771201A1 (en) 1997-05-07
DK0771201T3 (da) 2001-05-07
EP0771201A4 (en) 1997-09-10
FI970716A (fi) 1997-02-20
DE69520741T2 (de) 2001-10-11
ES2155895T3 (es) 2001-06-01
FI970716A0 (fi) 1997-02-20
PT771201E (pt) 2001-07-31
NO970787L (no) 1997-02-20
WO1996005832A1 (en) 1996-02-29
KR970705388A (ko) 1997-10-09
GR3036225T3 (en) 2001-10-31
MY131931A (en) 2007-09-28
AU3409895A (en) 1996-03-14
EP0771201B1 (en) 2001-04-18
NO970787D0 (no) 1997-02-20
ATE200623T1 (de) 2001-05-15
IL115018A0 (en) 1995-12-08
DE69520741D1 (de) 2001-05-23
CZ52297A3 (en) 1997-08-13
MX9701359A (es) 1997-05-31

Similar Documents

Publication Publication Date Title
AU7578794A (en) Methods for inhibiting endometriosis
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
IL111285A0 (en) Methods of inhibiting uterine fibrosis
HU9403663D0 (en) Methods of inhibiting dysfunctional uterine bleeding
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701333A (es) Metodos para inhibir el daño neuronal.
GR3036225T3 (en) Methods of inhibiting primary endometrial hyperplasia
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9706520A (es) Metodos para inhibir el cancer de ovario.